false0001110803 0001110803 2020-01-02 2020-01-02


Washington, D.C. 20549
Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 2, 2020
Illumina, Inc.
(Exact name of registrant as specified in its charter)

(Commission File Number)

(State or other jurisdiction of incorporation)
(I.R.S. Employer Identification No.)

5200 Illumina Way, San Diego, CA 92122
(Address of principal executive offices) (Zip code)
(858) 202-4500
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value
The NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act.     

Item 1.01. Entry into a Material Definitive Agreement

The disclosure under Item 1.02 is incorporated by reference.

Item 1.02. Termination of a Material Definitive Agreement.

As previously disclosed, on November 1, 2018, Illumina, Inc. (the “Company”) entered into an Agreement and Plan of Merger (as amended, the “Merger Agreement”) with Pacific Biosciences of California, Inc. (“PacBio”) and FC Ops Corp., a wholly owned subsidiary of the Company (“Merger Subsidiary”). On September 25, 2019, the Company, PacBio and Merger Subsidiary entered into Amendment No. 1 to the Merger Agreement to, among other things, extend the End Time (as defined in the Merger Agreement) to December 31, 2019, subject to the Company’s unilateral right to extend the End Time to March 31, 2020. On December 18, 2019, as previously announced, the Company elected to extend the End Time.

On January 2, 2020, the Company, PacBio and Merger Subsidiary entered into an agreement to terminate the Merger Agreement (the “Termination Agreement”). Pursuant to the Termination Agreement, (1) the Merger Agreement was terminated; (2) no later than January 6, 2020, the Company will make a cash payment to PacBio of $98 million (which amount constitutes the Reverse Termination Fee (as defined in the Merger Agreement)); and (3) the Company will make, which it would have been obligated to make under the Merger Agreement, cash payments to PacBio of $6 million on or before each of January 2, 2020, and March 2, 2020, and a cash payment to PacBio of $22 million on or before February 3, 2020 (the payments contemplated by this clause (3), the “Continuation Advances”).

However, pursuant to the Termination Agreement, in the event that, on or prior to September 30, 2020, PacBio enters into a definitive agreement providing for, or consummates, a Change of Control Transaction (as defined in the Termination Agreement), then PacBio will repay the Reverse Termination Fee (without interest) to the Company in connection with the consummation of such Change of Control Transaction. If such Change of Control Transaction is not consummated by the two-year anniversary of the execution of the definitive agreement for such Change of Control Transaction, then PacBio will not be required to repay the Reverse Termination Fee.

In addition, up to the full amount of the Continuation Advances actually paid to PacBio is repayable without interest to the Company if, within two years of March 31, 2020, PacBio enters into a Change of Control Transaction or raises at least $100 million in equity or debt financing in a single transaction (with the amount repayable dependent on the amount raised by PacBio).

The Company and PacBio mutually agreed to terminate the Merger Agreement as a result of the lengthy regulatory approval process both in the United States and United Kingdom, and uncertainties regarding the ultimate outcome of the regulatory process.

The foregoing summary of the Termination Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Termination Agreement, which is attached as Exhibit 10.1 and incorporated by reference herein.

Item 7.01. Regulation FD Disclosure.

On January 2, 2020, the Company and PacBio issued a joint press release announcing entry into the Termination Agreement (the “Press Release”). A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Item 7.01, including Exhibit 99.1, is furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

10.1 Agreement by and among Illumina, Inc., Pacific Biosciences of California, Inc., and FC Ops Corp., dated January 2, 2020.
99.1 Press Release, dated January 2, 2020.


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

January 2, 2020
/s/ Charles E. Dadswell
Charles E. Dadswell
Senior Vice President, General Counsel

Exhibit Index
Exhibit Number
Agreement by and among Illumina, Inc., Pacific Biosciences of California, Inc., and FC Ops Corp., dated January 2, 2020.
Press Release, dated January 2, 2020.

EX-10.1 2 exhibit101pacbio.htm EXHIBIT 10.1 Exhibit

This AGREEMENT, dated as of January 2, 2020 (the “Effective Date”), is entered into by and among Pacific Biosciences of California, Inc., a Delaware corporation (the “Company”), Illumina, Inc., a Delaware corporation (“Parent”), and FC Ops Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Subsidiary”). Each of the Company, Parent and Merger Subsidiary are sometimes referred to as a “Party.” Capitalized terms used in this Agreement and not otherwise defined have the meaning given to them in the Merger Agreement (as defined below).
WHEREAS, the Company, Parent and Merger Subsidiary previously entered into the Agreement and Plan of Merger, dated as of November 1, 2018, as amended by that certain Amendment No. 1, dated September 24, 2019 (the “Merger Agreement”); and
WHEREAS, the Parties desire to terminate, effective as of the Effective Date, the Merger Agreement.
NOW THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
Termination. As of the Effective Date, the Merger Agreement shall be terminated and be of no further force or effect, and no party thereto shall have any continuing liabilities, damages or obligations to the other party thereunder, except as expressly provided in this Agreement and pursuant to the Confidentiality Agreement.

Reverse Termination Fee. Notwithstanding anything to the contrary in the Merger Agreement, no later than January 6, 2020, the Reverse Termination Fee shall be paid by Parent to the Company by wire transfer of immediately available funds to an account or accounts designated by the Company. The Reverse Termination Fee will be repayable to Parent without interest by the Company solely in the event that, on or prior to September 30, 2020, the Company enters into a definitive agreement providing for, or consummates, a transaction described under clause (ii) or (iii) of the definition of Acquisition Proposal (with all percentages in the definition of Acquisition Proposal deemed to refer to 50%) had the Merger Agreement still been in effect (a “Change of Control Transaction”), but only if such Change of Control Transaction is consummated by the two-year anniversary of the execution of the definitive agreement for such Change of Control Transaction. Any repayment of the Reverse Termination Fee by the Company, if required, will occur in connection with, and be conditioned on, the consummation of such Change of Control Transaction. Other than as provided in this Section 2, the Parent Related Parties will have no right to recover the Reverse Termination Fee. For the avoidance of doubt, the Reverse Termination Fee will not be repayable, if required, on more than one occasion.

Continuation Advances. As previously contemplated by the Merger Agreement, Parent shall make a cash payment to the Company of $6 million on or before each of January 2, 2020, and March 2, 2020, and a cash payment to the Company of $22 million on or before February 3, 2020. Each payment made by Parent pursuant to this Section 3 as well as any amounts previously made by Parent pursuant to Section 10.03 of the Merger Agreement is referred to as a “Continuation Advance” (collectively, “Continuation Advances”) and will be made by wire transfer of immediately available funds to an account or accounts designated by the Company. The Company will use the Continuation Advances for general working capital purposes, including the repayment of debt. The Continuation Advances (including, without limitation, any Continuation Advances paid by Parent prior to the date hereof) will be repayable to Parent without interest by the Company solely in the event that, within two years following March 31, 2020, the Company enters into a definitive agreement providing for, or

consummates, (x) a Change of Control Transaction or (y) a single equity or debt financing (that may have multiple closings) with proceeds received by the Company of no less than $100 million (a “Qualifying Financing” and, together with a Change of Control Transaction, a “Repayment Transaction”). Any repayment of the Continuation Advances by the Company will occur in connection with, and be conditioned on, the consummation of the applicable Repayment Transaction. The amount repayable in connection with a Qualifying Financing will be calculated based on an increasing sliding scale (from 50% to 100%) of the Continuation Advances actually paid to the Company relative to the proceeds received by the Company in a Qualifying Financing between $100 million and $200 million, inclusive, with (A) 50% of the aggregate amount of Continuation Advances actually paid to the Company being repayable where the proceeds received by the Company in a Qualifying Financing are equal to $100 million and (B) 100% of the aggregate amount of Continuation Advances actually paid to the Company being repayable where the proceeds received by the Company in a Qualifying Financing are equal to or exceed $200 million. For illustrative purposes only, if the proceeds received by the Company in a Qualifying Financing are equal to $150 million, then 75% of the aggregate amount of Continuation Advances actually paid to the Company shall be repayable. In a Change of Control Transaction, 100% of the aggregate amount of Continuation Advances actually paid to the Company shall be repayable. Other than as provided in this Section 3, the Parent Related Parties will have no right to recover any Continuation Advance, including by offset of any Continuation Advance against the Reverse Termination Fee.

Public Announcements. Parent and the Company shall consult with each other before issuing any press release, making any other public statement or scheduling any press conference, conference call or meeting with investors or analysts with respect to this Agreement (except as may be required by applicable law or any listing agreement with, or rule of, any national securities exchange or association) and shall not (except as may be required by applicable law or any listing agreement with, or rule of, any national securities exchange or association) issue any such press release, make any such other public statement or schedule any such press conference, conference call or meeting before such consultation.

Further Assurances. Each Party, at its own expense, shall execute and deliver, or shall cause to be executed and delivered from time to time, such further certificates, agreements or instruments and shall take such other action as the other party hereto may reasonably request to document and effect the termination of the Merger Agreement and the transactions contemplated thereby.

Binding Nature of Agreement; No Third-Party Beneficiaries. This Agreement shall be binding upon and inure to the benefit of the parties, their respective heirs, successors and permitted assigns, executors, or other such beneficiaries. This Agreement is not intended to create, and shall not create, any rights in any person who is not a party to this Agreement.

Miscellaneous. The provisions of Section 11.01, Section 11.03, Section 11.04(a), Section 11.04(c), and Sections 11.06 through Section 11.13 of the Merger Agreement are hereby incorporated by reference in this Agreement with the same effect as if such provisions were set forth herein with the appropriate changes made.

[Remainder of page intentionally blank]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the date first above written.
By:    /s/ Stephen M. Moore
Name: Stephen M. Moore
Title: Vice President, General Counsel and Corporate Secretary
By:    /s/ Joydeep Goswami
Name: Joydeep Goswami
Title: Senior Vice President, Corporate Development and Strategic Planning
By:    /s/ Joydeep Goswami
Name: Joydeep Goswami
Title: Senior Vice President, Corporate Development and Strategic Planning

EX-99.1 3 exhibit991.htm EXHIBIT 99.1 Exhibit

Illumina and Pacific Biosciences Announce Termination of Merger Agreement

SAN DIEGO & MENLO PARK, Calif.- January 2, 2020 - Illumina, Inc. (NASDAQ: ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on November 1, 2018, under which Illumina would acquire Pacific Biosciences at a fully diluted enterprise value of approximately $1.2 billion in an all-cash transaction.

Considering the lengthy regulatory approval process the transaction has already been subject to and continued uncertainty of the ultimate outcome, the parties decided that terminating the agreement is in the best interest of their respective shareholders and employees. In accordance with the merger agreement, Illumina will pay Pacific Biosciences a termination fee of $98 million.

“We believe this proposed combination would have broadened access to Pacific Biosciences sequencing technology, significantly expanded and accelerated innovation, and ultimately increased the clinical utility and impact of sequencing,” said Francis deSouza, President and Chief Executive Officer of Illumina. “I’d like to thank our employees, as well as the Pacific Biosciences team, for their unwavering dedication and commitment throughout this process. Moving forward, we will continue to look for ways to increase the impact and benefit of sequencing technologies for researchers, clinicians, and most importantly, patients.”

“We are disappointed that our customers and other stakeholders will not realize the powerful advantages of integrating the sequencing capabilities of our two companies,” said Michael Hunkapiller, Ph.D., Chief Executive Officer of Pacific Biosciences. “With that said, we are confident in the future of Pacific Biosciences as we continue to pursue improved sequencing accuracy and throughput that can be utilized in an ever-expanding number of applications.”

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future improvements in the technology of each of Illumina and Pacific Biosciences, the growth of each company, the expansion of the applications for each company’s products and technology, and other future events. You should not place undue reliance on forward-looking statements because they involve

known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond each of Illumina’s and Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Illumina’s and Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Illumina’s and Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Each of Illumina and Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Illumina Contacts

Jen Carroll
(858) 449-8082
Jacquie Ross, CFA
(858) 882-2172

Pacific Biosciences Contact

Ben Gong
(650) 521-8203

EX-101.SCH 4 ilmn-20200102.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 ilmn-20200102_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 6 ilmn-20200102_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 ilmn-20200102_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover Page [Abstract] Cover Page [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 8 ilmn-20200102_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 97 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Cover Page Document Sheet http://www.illumina.com/role/CoverPageDocument Cover Page Document Cover 1 false false All Reports Book All Reports form8-kpacbioterm.htm exhibit101pacbio.htm exhibit991.htm ilmn-20200102.xsd ilmn-20200102_cal.xml ilmn-20200102_def.xml ilmn-20200102_lab.xml ilmn-20200102_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end ZIP 13 0001110803-20-000005-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001110803-20-000005-xbrl.zip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end XML 14 form8-kpacbioterm_htm.xml IDEA: XBRL DOCUMENT 0001110803 2020-01-02 2020-01-02 false 0001110803 8-K 2020-01-02 Illumina, Inc. 001-35406 DE 33-0804655 5200 Illumina Way San Diego CA 92122 858 202-4500 false false false false Common Stock, $0.01 par value ILMN NASDAQ false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-kpacbioterm.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "ilmn-20200102_cal.xml" ] }, "definitionLink": { "local": [ "ilmn-20200102_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "form8-kpacbioterm.htm" ] }, "labelLink": { "local": [ "ilmn-20200102_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ilmn-20200102_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "ilmn-20200102.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ilmn", "nsuri": "http://www.illumina.com/20200102", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "form8-kpacbioterm.htm", "contextRef": "D2020Q1SD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page Document", "role": "http://www.illumina.com/role/CoverPageDocument", "shortName": "Cover Page Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "form8-kpacbioterm.htm", "contextRef": "D2020Q1SD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "ilmn_CoverPageAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover Page [Abstract]", "label": "Cover Page [Abstract]" } } }, "localname": "CoverPageAbstract", "nsuri": "http://www.illumina.com/20200102", "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 16 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Page Document
Jan. 02, 2020
Cover Page [Abstract]  
Document Type 8-K
Document Period End Date Jan. 02, 2020
Entity Registrant Name Illumina, Inc.
Entity File Number 001-35406
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 33-0804655
Entity Address, Address Line One 5200 Illumina Way
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92122
City Area Code 858
Local Phone Number 202-4500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol ILMN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001110803
Amendment Flag false